法洛四联症修复后肺动脉瓣置换的倾向评分校正结局分析
本研究基于国际注册研究,纳入977例法洛四联症修复后(rTOF)患者,采用倾向评分校正基线差异,分析肺动脉瓣置换(PVR)与死亡及持续性室速的关联。结果显示PVR与主要终点(死亡/持续性室速)风险降低无关(HR 0.65,95%CI 0.31-1.36),在未达共识标准者中PVR后次要终点事件更多(HR 2.31,95%CI 1.07-4.97)。
要点
- PVR未显著降低rTOF患者死亡及持续性室速风险。
- 未达共识标准者PVR后次要终点事件风险增加。
- 需谨慎选择PVR适应证,避免不必要干预。
核心结论
- 在rTOF患者中,PVR与平均5.3年随访期内死亡和持续性室速风险降低无关。
- 未达共识标准者中,PVR后次要终点事件更多。
研究设计与样本
- 国际注册研究,纳入977例rTOF患者,年龄26±15岁,45%接受PVR,随访5.3±3.1年。
- 采用倾向评分校正基线差异,PVR作为时变协变量分析。
主要发现
- 主要终点(死亡/持续性室速)在41例中发生,次要终点在88例中发生。
- PVR与主要终点HR 0.65(95%CI 0.31-1.36;P=0.25),次要终点HR 1.43(95%CI 0.83-2.46;P=0.19)。
- 未达共识标准者(n=426)中,PVR与主要终点HR 2.53(95%CI 0.79-8.06;P=0.12),次要终点HR 2.31(95%CI 1.07-4.97;P=0.03)。
关键数值与推荐
- PVR共识标准:肺动脉反流>25%且满足以下至少2项:右室舒张末容积>160 mL/m2、右室收缩末容积>80 mL/m2、右室射血分数<47%、左室射血分数<55%、QRS时限>160 ms。
临床怎么用
- 对于rTOF患者,PVR决策需综合评估,尤其未达共识标准者应谨慎。
- PVR可能不改善短期死亡和持续性室速风险,需个体化权衡。
局限性
- 观察性研究,可能存在残余混杂。
- 随访时间平均5.3年,长期结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the association of pulmonary valve replacement (PVR) with death and sustained ventricular tachycardia (VT) in patients with repaired tetralogy of Fallot (rTOF). METHODS: Subjects with rTOF and cardiac magnetic resonance from an international registry were included. A PVR propensity score was created to adjust for baseline differences. PVR consensus criteria were predefined as pulmonary regurgitation >25% and ≥2 of the following criteria: right ventricular (RV) end-diastolic volume >160 mL/m2, RV end-systolic volume >80 mL/m2, RV ejection fraction (EF) <47%, left ventricular EF <55% and QRS duration >160 ms. The primary outcome included (aborted) death and sustained VT. The secondary outcome included heart failure, non-sustained VT and sustained supraventricular tachycardia. RESULTS: In 977 rTOF subjects (age 26±15 years, 45% PVR, follow-up 5.3±3.1 years), the primary and secondary outcomes occurred in 41 and 88 subjects, respectively. The HR for subjects with versus without PVR (time-varying covariate) was 0.65 (95% CI 0.31 to 1.36; P=0.25) for the primary outcome and 1.43 (95% CI 0.83 to 2.46; P=0.19) for the secondary outcome after adjusting for propensity and other factors. In subjects (n=426) not meeting consensus criteria, the HR for subjects with (n=132) versus without (n=294) PVR was 2.53 (95% CI 0.79 to 8.06; P=0.12) for the primary outcome and 2.31 (95% CI 1.07 to 4.97; P=0.03) for the secondary outcome. CONCLUSION: In this large multicentre rTOF cohort, PVR was not associated with a reduced rate of death and sustained VT at an average follow-up of 5.3 years. Additionally, there were more events after PVR compared with no PVR in subjects not meeting consensus criteria.
引用
- Bokma JP, Geva T, Sleeper LA, et al. A propensity score-adjusted analysis of clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Heart. 2017. PMID: 29092913. doi:10.1136/heartjnl-2017-312048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。